Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.
The investigators plan to measure these factors prior to and after bronchoscopy.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.|
- Volume of blood loss during the procedure [ Time Frame: 1 day ] [ Designated as safety issue: No ]
|Study Start Date:||June 2009|
|Study Completion Date:||October 2011|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Comparison between individuals with and without pulmonary malignancy
This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00929565
|United States, Oklahoma|
|VA Medical Center|
|Oklahoma City, Oklahoma, United States, 73104|
|Principal Investigator:||Jijo John, MD||University of Oklahoma|